Skip to Content

Combidex Approval Status

Combidex (ferumoxtran-10) is a investigational functional molecular imaging agent intended for use in conjunction with magnetic resonance imaging (MRI) to aid in the differentiation of cancerous from non-cancerous lymph nodes.

In March 2005, Advanced Magnetics, Inc. announced the receipt of an Approvable Letter from the U.S. Food and Drug Administration (FDA) requesting additional data to demonstrate the efficacy of Combidex (ferumoxtran-10).

Development Status and FDA Approval Process for Combidex

Mar 24, 2005Advanced Magnetics, Inc. Receives Approvable Letter From FDA For Combidex
Mar  3, 2005Oncologic Drugs Advisory Committee Recommends Against Approval of a Broad Indication For Combidex
Feb  1, 2005Advanced Magnetics' Combidex to be Reviewed by FDA Oncologic Drugs Advisory Committee

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.